Weight Loss Jabs and Ozempic: Understanding the Risks and Benefits

Image credits: Michael Siluk/UCG/Universal Images Group via Getty Images

The use of weight loss jabs, including Ozempic, has been linked to a number of deaths in the UK, according to reports from the Medicines and Healthcare products Regulatory Agency (MHRA). However, experts say that the benefits of these medications outweigh the risks when used correctly, with proper medical supervision and informed decision-making. The MHRA has reported 82 deaths associated with the use of GLP-1 RA receptor agonist drugs, including Mounjaro, Wegovy, and Ozempic, up to January 2025. Of these, 22 deaths were linked to the use of the medications for weight loss, while the remaining 60 were associated with the treatment of type 2 diabetes.

Medical experts have called for further investigation into the deaths, but emphasize that the number of fatalities is relatively low compared to the number of people using the medications. They also stress that weight loss medication is safe when used under the right supervision, and that the benefits of the medications, including the reduction of the risk of heart attack and stroke, outweigh the potential risks. The MHRA has made clear that the figures do not necessarily mean that the medications have caused the deaths or hospitalizations, but rather that a reporter has suspected a link. The data on hospitalizations and deaths are gathered as part of the regulator's "yellow card" scheme, which tallies all reports of adverse reactions to medicines.

Some patients taking the weight loss jabs have experienced gastrointestinal side effects, such as nausea, vomiting, and diarrhea, while others have reported more serious side effects, including gastritis and pancreatitis. However, manufacturers of the weight loss jabs say that they have been extensively trialed and examined before being made available to patients, and that any reported side effects are closely monitored. The MHRA's chief safety officer, Dr. Alison Cave, has stated that relatively new medicines, such as weight loss drugs, are more intensively monitored to ensure that any new safety issues are identified promptly, and that the benefits of GLP-1 RAs outweigh the potential risks when used for licensed indications.

Health experts have warned that it is too easy to buy black-market jabs sold on social media, and that some patients may be using them without a proper prescription. They have also emphasized the importance of proper medical supervision and informed decision-making when using weight loss medications. The Royal Pharmaceutical Society's president, Professor Claire Anderson, has called for further investigation by the MHRA to better understand any potential risks associated with the medications. Meanwhile, the Department of Health and Social Care has stated that weight loss drugs can be "game-changers in tackling obesity", but also warned that "they're not a quick fix to lose a few pounds".

In conclusion, while the reports of deaths linked to weight loss jabs, including Ozempic, are concerning, the benefits of these medications outweigh the risks when used correctly, with proper medical supervision and informed decision-making. It is essential to continue monitoring the safety of these medications and to ensure that patients are fully informed of the potential risks and benefits. The following list highlights the key points to consider: * 82 deaths have been reported in association with the use of GLP-1 RA receptor agonist drugs, including Mounjaro, Wegovy, and Ozempic * 22 deaths were linked to the use of the medications for weight loss * The benefits of the medications, including the reduction of the risk of heart attack and stroke, outweigh the potential risks * Proper medical supervision and informed decision-making are essential when using weight loss medications * The MHRA continues to monitor the safety of these medications and encourages patients and healthcare professionals to report any suspected side effects.